2020 Virtual UK Oncology Forum Programme

BASO (DAY ONE ONLY)
SESSION CHAIR - MR ZAED HAMADY (BASO VICE PRESIDENT) + BASO TRUSTEE (TBC)

Synopsis : TBC
Chair: Mr Zaed Hamady, Vice President BASO~ACS
‘Welcome & introduction’

Professor Jayant Vaidya, Professor of Surgery and Oncology, University College London
‘TARGIT-IORT for breast cancer’

Mr Myrddin (Merv) Rees, Consultant General & Hepatobiliary Surgeon Basingstoke & North Hampshire Hospital
‘Debulking surgery for colorectal liver metastasis ‘

Professor Alex Mirnezami, Professor of Surgical Oncology & Consultant Colorectal Surgeon, Southampton General Hospital
‘IORT in Gastro Intestinal Surgery’

Mr Zaed Hamady, Consultant General & Hepatobiliary Surgeon Southampton University Hospital
‘Cancer Surgery and Covid-19’

Expert Panel
‘Discussion Session on ‘surgical input at MDMs’’

Mr Zaed Hamady, Vice President BASO~ACS
‘Q&A, Chairman’s thoughts, wrap up and evaluation’

Synopsis :
Welcome to our new format breast cancer sessions in UK Oncology Forum 2020. With have an exciting agenda this year in a live digital format with interactive discussions. We will be looking at all that is new in breast cancer in the last 12 months, particularly areas that may change our understanding and practice. Many women live with secondary breast for years- is it time we took a different perspective on this diagnosis reflecting outcomes more. We also take a surgical perspective to secondary disease and explore the role of local surgical treatments and benefits for people. Of course no session is complete without looking at the effects of COVID for people with breast cancer in the last months, both medically and socially. We all look forward to seeing all on our screens!

Dr Marina Parton & Dr Mark Verrill
‘Welcome & Introduction’

Dr Olga Oikonomidou
’What’s new in breast cancer in the past year’ 

Mr Stuart McIntosh
‘Surgery in MBC’ 

Professor Andrew Wardley
‘Breast Cancer as a Chronic Disease’

Ms Karen Verrill
‘Cancer doesn’t stop because of Coronavirus’

Expert Panel
‘Discussion’

Dr Marina Parton & Dr Mark Verrill
‘Q&A, Chairman’s thoughts, wrap up and evaluation’

COLORECTAL CANCER (BOTH DAYS)
SESSION CHAIR - DR VICKY COYLE

Synopsis : TBC

Dr Vicky Coyle
‘Welcome & Introduction’

Dr Naureen Starling
‘ ctDNA guided treatment in colorectal cancer’

Dr Paul Ross
Assessment and management of older patients with CRC

Dr Jenny Seligmann
‘ASCO & ESMO CRC highlights and insights ‘

Expert Panel
‘Discussion’

Dr Vicky Coyle
‘Q&A, Chairman’s thoughts, wrap up and evaluation’

GYNAE~ONCOLOGY CANCER (BOTH DAYS)
SESSION CHAIR - DR REBECCA KRISTELIET

Synopsis : TBC

Dr Rebecca Kristeleit, Chair
‘Welcome & Introduction’

Professor James Brenton
'Genetic testing, genomics and HRD in ovarian cancer and possible extension to endometrial cancer'
 
Dr Yvette Drew
‘Updates on the systemic management of advanced Endometrial cancer’ 

Dr Dennis Hadjiyiannakis
‘Hot topics in current gynae radiotherapy’

Dr Carien Creutzberg
‘GCIC endometrial cancer translational research’

Expert Panel
‘Discussion’

Dr Rebecca Kristeleit, Chair
‘Q&A, Chairman’s thoughts, wrap up and evaluation’

HEAD & NECK ( DAY ONE ONLY)
SESSION CHAIR - PROFESSOR TERRY JONES

Synopsis : TBC

Professor Terry Jones
‘Welcome & Introduction’

Dr David Thomson
'The future role of proton therapy in the management of head and neck cancer'

Professor Christian Simon
'New Frontiers in H&N Cancer Treatment a surgical perspective'

Professor Mererid Evans
'De-intensification treatment strategies for HPV-positive oropharynx cancer'


Dr Martin Forster
'H&N highlights from ASCO & ESMO'
 
Expert Panel
‘Discussion’

Professor Terry Jones, Chair
‘Q&A, Chairman’s thoughts, wrap up and evaluation’

LIVER & PANCREATIC CANCER (DAY ONE ONLY)
SESSION CO CHAIR - PROFESSOR DEREK O’REILLY & ANITA BALAKRISHNAN 

Synopsis : TBC

Professor Derek O’Reilly
‘Welcome & Introduction’

Dr Ganash Radhakrishna
‘Irradiating the liver: adding insult to injury?’

Professor John Bridgewater
'New EPOC - trials and tribulations'

Dr David Chang
‘Precision-Panc platform; precision medicine in pancreatic cancer and integrating chemotherapy, rad and surgery in clinical trials and in practice.’

Professor Eithne Costello
‘UK-EDI study ’

Expert Panel
‘Discussion’

Professor Derek O’Reilly    
‘Q&A, Chairman’s thoughts, wrap up and evaluation’

LUNG CANCER (BOTH DAYS)
SESSION CHAIR - DR FIONA MCDONALD

Synopsis : TBC

Dr Fiona McDonald
‘Welcome & Introduction’

Dr Riyaz Shah
‘What is new in the mutation positive disease population? ‘

Tom Newsom-Davis
‘How do we treat patients with no actionable mutations? ‘

Professor Matthias Guckenberger, Zurich
‘What is the role of radiotherapy in metastatic lung cancer? ‘

Professor Samreen Ahmed
‘How do we treat patients with small cell lung cancer & does radiotherapy still have a role? ‘

Expert Panel
‘Discussion’

Dr Fiona McDonald
‘Q&A, Chairman’s thoughts, wrap up and evaluation’

MELANOMA (DAY ONE ONLY)
SESSION CHAIR - PROFESSOR RUTH PLUMMER

Synopsis :
This tumour site specific session will update the audience on the recent advances in treatment of melanoma with a multi-disciplinary team of speakers covering all aspects of management. Updates from the two major international cancer research conferences will provide the latest clinical trial data, in addition to presentations on cutting edge science in the clinic. The interactive session will allow the audience to discuss and debate changes in management that have been needed during the pandemic, and explore best practice in this area.

Professor Ruth Plummer    
‘Welcome & Introduction’

Dr Joe Sacco
'Intralesional therapy- harnessing the abscopal effect'

Mr Howard Peach
'Covid pandemic altered the management of patients with melanoma'

Dr Sophie Papa
'Updates from ASCO & Melanoma'

Dr Christian Blank 
‘Neoadjuvant treatment of stage III melanoma’

Expert Panel 
‘Discussion’

‘Q&A, Chairman’s thoughts, wrap up and evaluation’

RADIOTHERAPY (BOTH DAYS)
SESSION CHAIR - DR ALISON TREE

Synopsis : ‘The radiotherapy revolution?
Radiotherapy - boring, archaic and toxic or exciting, innovative and crucial to cancer treatment? Did you know that 50% of patients cured of cancer have radiotherapy? Come and find out how immunotherapy, protons, ablation of metastases and personalised care for an ageing population is revolutionising radiotherapy in the UK’

Dr Alison Tree
‘Welcome & Introduction’

Professor Neil Burnet
‘Protons: more hype than substance?’

Dr Anthea Cree
‘Radiotherapy for the older cancer patient’

Dr Nora Sundahl
‘The abscopal effect – rarer than unicorns?’

Dr David Palma
‘Stereotactic radiation for metastases: taking it from oligomets to ARREST’

Expert Panel
‘Discussion’

Dr Alison Tree
‘Q&A, Chairman’s thoughts, wrap up and evaluation’

PROSTATE CANCER (BOTH DAYS)
SESSION CHAIR - DR NICK VAN AS

Synopsis : ‘ Local (primary and mets) and potentially combination treatment strategies in systemic disease: Who? When ? How ? and what next?’

Dr Nick Van As, Chair
‘Welcome & Introduction’

Mr P. Sooriakumaran
‘Surgery’

Dr Aidan Cole (Day 1) & Professor Joe O'Sullivan (Day 2)    
‘Bone health agents in men with metastatic prostate cancer ‘

Dr Alison Reid
'Systemic therapies’

Dr Barbara Jereczek-Fossa
'Local radiotherapy in systemic disease: a new paradigm?’

Expert Panel
‘Discussion’

Dr Nick Van As, Chair
‘Q&A, Chairman’s thoughts, wrap up and evaluation’

RENAL & BLADDER JOINT SESSION (BOTH DAYS)
CO SESSION CHAIR - Prof Peter Hoskin (R) / Professor Ananya Choudhury (B) 

Synopsis: Systemic treatment options in renal cancer have expanded dramatically in the past decade with the evolution of effective immunomodulating agents which have transformed the prognosis for patients with metastatic disease. In this session we will provide an overview of the agents now available and consider the optimal sequencing where multiple agents are available.
Bladder preservation is increasing in prominence when considering curative treatment of muscle invasive bladder cancer using trimodality therapy incorporating radiotherapy and a radiosensitiser. Personalised optimisation of treatment is the ultimate goal of any cancer therapy. Identification of predictive biomarkers is key to this and is the subject of the final component of this session.

Objectives:
Gain knowledge of the available systemic treatments for renal cancer
Understand the rationale for different sequencing of systemic therapies
Discuss the role of biomarkers in personalising management of muscle invasive bladder cancer

Prof Peter Hoskin (R) / Professor Ananya Choudhury (B)
‘Welcome & Introduction’

Dr Simon Crabb
'Newer classifications around Bladder/Kidney treatment'

Mr Rajesh Nair
‘Urology Upper tract surgery’

Dr Manon Pillai
‘Kidney sequencing’

Prof Ananya Choudhury
 'A personalised approach to bladder radiotherapy"

Expert Panel 
‘Discussion’

Prof Peter Hoskin (R) / Professor Ananya Choudhury (B)
‘Q&A, Chairman’s thoughts, wrap up and evaluation’

UKONS (DAY ONE ONLY)
SESSION CHAIR - KAY BELL SUPPORTED BY MARK FOULKES

Synopsis : Sexual Health and Cancer
‘To raise awareness of the challenges and issues, patients with cancer experience in relation to sexual health, considering both the physical and emotionally effects in context.’

Kay Bell
‘Welcome & Introduction’

Dr Jane Frankland
‘Sexual well-being among people living with and beyond cancer: findings from the Macmillan CREW and HORIZONS cohort studies’

Clare Johnson
‘Experiences of breast cancer treatment on body image’

Liz O’Riordan
‘Whose job is it to talk about sex anyway?’

Dr Alison May Berner
‘Providing personalised care for gender diverse patients ’

Expert Panel
‘Discussion’

Kay Bell
‘Q&A, Chairman’s thoughts, wrap up and evaluation’

BRAIN METASTASES AND GLIOMAS (DAY TWO ONLY)
SESSION CHAIR - CATHERINE MCBAIN

Synopsis :
This session will provide a comprehensive update on management of brain metastases, including available treatment options and factors which influence patient selection and MDT decision making. State of the art neurosurgery, stereotactic radiosurgery (SRS) and systemic therapy will be described. Choice and sequencing of these treatments will be illustrated and discussed via a series of case histories, deliberately selected to highlight controversies in this field.
The session will also include an update on systemic and novel therapies for gliomas, including the status of personalised medicine, immunotherapy and tumour-agnostic agents in primary brain tumours. The session aims to whet the appetite of non-neuro-oncologists by highlighting the challenges and opportunities in this field.

09:00hrs ~ 09.10hrs -  Welcome & introduction (Dr Catherine McBain)
09:10hrs ~ 09.35hrs - Modern neurosurgical thinking and techniques in brain tumours  (Mr Pietro D-Urso)
09:35hrs ~ 10.00hrs - Systemic therapies for gliomas: Challenges and opportunities (Dr Fiona Collinson)
10:00hrs ~ 10:15hrs - Radiotherapy and SRS for brain metastases (Dr Paul Sanghera)
10:15hrs ~ 10:30hrs - Systemic therapy for brain metastases (Dr Gary Doherty)
10:30hrs ~ 11:25hrs - Multidisciplinary management of brain metastases: case histories with discussion and questions
11:25hrs ~ 11:30hrs - Conclusion and close (Dr Catherine McBain)

MACMILLAN GP (DAY ONE ONLY)
SESSION CHAIR - DR ANTHONY CUNLIFFE

Synopsis : ‘ Personalised care and cancer- it’s everyone’s business’

Dr Anthony Cunliffe
‘Welcome & Introduction’

Ensuring that people living with cancer receive personalised care is everyone’s business, with contacts from the point of diagnosis, through prehabilitation, making treatment decisions and going through treatment, acutely unwell episodes, good quality cancer care review conversations, needs assessments, gaining support from social prescribers and courageous end of life care conversations.

In this workshop, we’ll explore how we can build on the strengths of the multiple different professionals involved in delivering care to people following a cancer diagnosis by focusing on the unique touchpoints and opportunities they have. Through the use of case studies, we’ll generate an interactive conversation based around the key times of need experienced by cancer patients to draw out what each individual can bring to achieving personalised care.

Subjects to be covered:-

Delivering personalised care at:

• The point of diagnosis

• Prehabilitation

• Treatment including the acutely unwell patient

• Cancer Care Reviews

• Communication across pathways including the use of the electronic Holistic Needs Assessment in the community and utilisation of Treatment Summaries

• Social Prescribing

• Courageous conversations at the end of life

Dr Anthony Cunliffe
Dr Ashling Lillis    
Sophia Nicola
June Davis
Dr Anthony Cunliffe
‘Q&A, Chairman’s thoughts, wrap up and evaluation’

UPPER GI (DAY TWO ONLY)
SESSION CO CHAIR - DR JANET GRAHAM / PROFESSOR RUSSELL PETTY

Synopsis :
In this interactive session we will discuss state of the art multidisciplinary management of gastric and oesophageal cancer . Talks will cover recent advances in radiotherapy, surgery and systemic therapy and provide trial and clinical research updates including those recently presented at ASCO 2020 and ESMO 2020 focussing on the impact trial results have for clinical practice .

At the end of this session attendees should have gained :
• An understanding of the clinical role of radiotherapy dose escalation ,SABR, and proton therapy in oesophageal cancers including how targeted therapies might be integrated.
• An understanding of the role of robotic assisted surgery in gastric and oesophageal cancers and how outcomes compare to conventional surgery
• An understanding of how emerging clinical trial data and liquid tumour biopsy technology can be applied to improve the treatment of drug resistant gastric and oesophageal cancers
• An understanding of the emerging role and clinical use of immune checkpoint inhibitors in gastric and oesophageal cancers as informed by latest clinical trial results
• An understanding of how neo-adjuvant and adjuvant treatments can be optimised for each gastric and oesophageal cancer patient and ongoing clinical trials in this area. 

Dr Janet Graham/Professor Russell Petty
‘Welcome & Introduction’

Professor Maria Hawkins
‘Advances in radiotherapy and what’s on the horizon for OG cancer’

Prof Tim Underwood
‘Minimally invasive surgery and the role of robotic surgery ‘

Professor Russell Petty
‘Precision medicine in biology OG’

Dr Naureen Starling
‘The role of IO in OG cancers and where the field currently is (ASCO Updates)’

Professor Saleh Al-Batran (Germany)
‘Optimal (neo) adjuvant treatment’

Expert Panel
‘Discussion’

Dr Janet Graham/Professor Russell Petty
‘Q&A, Chairman’s thoughts, wrap up and evaluation’

UKOMiC (DAY TWO ONLY)
SESSION CHAIR - DR CHARLES KELLY

UKOMiC Workshop UK Oncology Forum: Friday 25th September 09.00-11.30.


Welcome to the UKOMiC/UK Oncology Forum ‘Oral Care in Cancer Workshop’. The workshop will be led by dental, oncologist and nursing experts from the UK and the European Oral Care in Cancer Expert Working Groups. The speakers and workshop we will present and explore - advances in cancer treatments and the impact on the oral/dental cavity, the role of dentistry in the head and neck setting, the importance of multi-professional working, addressing graft versus host disease and ways to improve working between the hospital and community settings.


Dr Charles Kelly (Chair) - Welcome & Introduction

09.00hrs ~ 09:20hrs - Dr Clare Morgan
Dentistry in the head and neck cancer setting

09:20hrs ~ 09:25hrs - Chair Q&A

09:25hrs ~ 09:45hrs - Dr Barry Quinn
New advances and oral care

09:45hrs ~ 09:50hrs Chair  - Q&A

09.50hrs ~ 10:00hrs -- Break

10:00hrs ~ 10:20hrs - Dr Marinka Mravak-Stipetic
A team approach and managing graft versus host disease

10:20hrs ~ 10.25hrs - Chair  - Q&A

10.25hrs ~ 10.45hrs - Ms Joss Harding
Working with community services

10.45hrs ~ 10:50hrs Chair - Q&A

10.50hrs ~ 11.20hrs - Expert Panel Interactive discussion

11:20hrs ~ 11.30hrs Chair - Thoughts, evaluation and summary